289 results about "Cardiac functioning" patented technology

The invention provides a four-dimensional cardiac function imaging method and device based on a biological magnetic signal. The method comprises the following steps: acquiring a magnetocardiogram signal of a to-be-detected object and dynamic structure information of a target trunk part in a full cardiac cycle; wherein the target trunk part at least comprises double lungs, a trunk, a heart cavity of the trunk and a pericardium structure, and the dynamic structure information comprises a contour structure and a multi-frame dynamic image; performing spatial registration on the dynamic structure information and the sensor for acquiring the magnetocardiogram signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; according to the dynamic structure information, the coordinate of the sensor and the magnetocardiogram signal, calculating and reconstructing cardiac electrical excitation activity to obtain a calculation and reconstruction result; and converting the calculation reconstruction result into a four-dimensional visual image. According to the method, heart magnetic imaging and heart movement are combined, on the basis of obtained dynamic structure information and heart magnetic signals, the characteristics of biological magnetic signals are fully utilized, and the signal processing technology is integrated through space registration, so that accurate reconstruction of four-dimensional representation of the heart and visual display of functional activities are realized; therefore, the obtained four-dimensional visual image can completely represent the dynamic electrophysiological activities of the whole heart (including epicardium, endocardium and intrawall tissues) in a cardiac cycle, and a technical scheme with different concepts is provided for non-invasive imaging of cardiac electrical excitation activities.

Coaptation assist device for repairing cardiac valves and associated systems and methods are disclosed herein. A coaptation assist device configured in accordance with embodiments of the present technology can include, for example, a fixation member configured to press against cardiac tissue proximate to a native valve annulus, and a stationary coaptation structure extending away from the fixation member. The coaptation structure can include an anterior surface configured to coapt with a first native leaflet during systole and a posterior surface configured to displace at least a portion of a second native leaflet. The device also includes at least one sensor configured to detect parameters associated with at least one of cardiac function and device functionality. The sensors can be pressure sensors configured to detect left atrial pressure and / or left ventricular pressure.

The invention discloses a convolutional neural network information processing method for heart function dynamic monitoring, and belongs to the technical field of medical detection and monitoring. Comprising the following steps that multi-mode electrocardiosignal data and current physiological state parameters of a patient are obtained, and initial configuration of the intelligent heart function monitoring device is obtained; determining the signal quality grade of each signal channel, and generating a dynamic filtering adjustment strategy of the multi-modal signal acquisition module; configuring a feature extraction strategy of a double-branch convolutional neural network module based on the signal features of the target analysis signal segment and the physiological state parameters; performing multi-scale time sequence feature extraction and frequency domain autonomic nerve regulation feature extraction on the target analysis signal segment by using a double-branch convolutional neural network module according to a feature extraction strategy; executing arrhythmia classification, heart rate variability parameter quantification, heart function evaluation grade and graded early warning tasks, and outputting multi-stage intelligent early warning information from normal monitoring, potential risk and abnormal early warning to an emergency state.

The invention discloses a multi-mode-based flexible wearable heart function monitoring method, system and device, and relates to the technical field of health monitoring, and the method comprises the steps: outputting a multi-mode signal through a flexible patch sensing module when the flexible patch sensing module is arranged in a detection area; wherein the flexible patch sensing module comprises an electrocardio sensor, a pulse wave sensor, a heart sound sensor, a strain sensor and a microfluidic biosensor. According to the invention, high-precision synchronous signal acquisition is realized through flexible patch integrated multi-modal sensing, heart multi-source signal features are adaptively extracted in combination with a multi-scale convolutional neural model, and timing sequence relevance is captured by using a bidirectional long-short-term memory network, so that the accuracy and reliability of heart disease diagnosis are remarkably improved, and the accuracy and reliability of heart disease diagnosis are improved. Meanwhile, non-invasive and continuous monitoring and early pathological screening are supported.

The invention relates to application of an MYZAP overexpression vector in preparation of a medicine for preventing and treating MIRI, and belongs to the technical field of biological medicine. In order to solve the problem that application of gene drugs in prevention and treatment of myocardial ischemia reperfusion injury is limited, the invention provides application of an MYZAP gene overexpression recombinant vector in preparation of drugs for prevention and treatment of myocardial ischemia reperfusion injury, and the MYZAP gene overexpression recombinant vector is an adeno-associated virus vector AAV9-MYZAP for overexpressing MYZAP. Experiments prove that MYZAP overexpression can improve the cardiac function after myocardial ischemia reperfusion, reduce the occurrence rate of arrhythmia and improve the functions of sodium ion channels, potassium ion channels and calcium ion channels of myocardial cells. On the basis, the invention further provides a medicine for preventing and treating myocardial ischemia reperfusion injury, a new strategy is provided for gene therapy of myocardial ischemia reperfusion injury, and the medicine has a wide clinical application prospect.

The invention provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disturbance. The monascus composition comprises one or more of cortex mori, ramulus mori and folium mori, monascus and radix puerariae. When the composition containing the red yeast rice is applied to preparation of the medicine for preventing and / or controlling coronary microcirculation disturbance, the abnormal microvascular structure can be improved (myocardial microvascular density MVD is increased, edema around microvessels is relieved, the lumen stenosis phenomenon is improved, and the endothelial cell condition is good); 2) microvascular occlusion is improved (pathologic results show that microvascular contents are reduced); (3) the abnormal vasodilatation and contraction function of the microvessels is improved (NO is increased); 4) improving blood lipid metabolism disorder; and (5) the heart function is improved (the left ventricular ejection fraction LVEF and the left ventricular short axis shortening rate LVFS are improved, and the left ventricular pressure maximum rising rate LV + dp / dtmax and the left ventricular pressure maximum falling rate LV-dp / dtmax are increased).

The systems, devices, and methods presented herein use a heart pump to obtain measurements of cardiovascular function. The heart pumps described herein can operate in parallel with and unload the heart. The system can quantify the functioning of the native heart by measuring certain parameters / signals such as pressure or motor current, then calculate and display one or more metrics of cardiovascular function. These metrics, such as left ventricular end diastolic pressure (LVEDP), left ventricular pressure, and contractility, provide valuable information to a user regarding a patient's state of heart function and recovery.

The invention discloses a cardiac function rehabilitation state monitoring method for coronary heart disease postoperative population. The method comprises the following steps: constructing a third-order dynamic baseline adaptive to postoperative pathological evolution; carrying out stress-physiological coupling modeling on the basis of a double-AI (Artificial Intelligence) collaborative architecture; and carrying out trend early warning of equal-condition longitudinal pairing. The heart function rehabilitation state monitoring system comprises an electrocardiosignal preprocessing unit, the electrocardiosignal preprocessing unit is connected with a multi-dimensional electrocardiosignal feature extraction unit, and the multi-dimensional electrocardiosignal feature extraction unit is connected with a third-order individualized baseline management unit and a front stress recognition AI unit. And the third-order individualized baseline management unit and the front stress identification AI unit are respectively connected with the core correlation deduction AI unit. According to the method and system for monitoring the cardiac function rehabilitation state of the crowd after the coronary heart disease operation, dynamic baseline construction and the pathological evolution rule after the coronary heart disease operation are deeply bound, and the problem of high false alarm of a traditional fixed baseline in the early stage of the operation is thoroughly solved through triple-stage design and a dual calibration mechanism.

A method for assisting a heart ventricle can comprise providing a longitudinally expandable member that is reversibly expandable along a longitudinal dimension, wherein the longitudinally expandable member can include adjacent abutting portions meeting at respective bends that form acute angles along the longitudinal dimension. The method can include securing a first end portion of the longitudinally expandable member to a first wall portion of the heart ventricle via a first anchor engagement feature associated with the first end portion. The method can include securing a second end portion of the longitudinally expandable member to a second wall portion of the heart ventricle via a second anchor engagement feature associated with the second end portion, the plurality of bends between the first and second end portions allowing augmenting expansion of the heart ventricle using spring force of the longitudinally expandable member to thereby improve heart function.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

The invention discloses a cardiac functional region modeling method based on a deep generative adversarial network. The method comprises the following steps: S1, collecting cardiac medical image data; s2, constructing a cardiac medical image data set; s3, constructing an improved deep generative adversarial network; s4, inputting the preprocessed cardiac medical image data into an improved deep generative adversarial network, and outputting a cardiac functional region segmentation prediction result by a generator of the improved deep generative adversarial network; s5, optimizing network parameters of the generator and the discriminator; and S6, performing reasoning calculation on the preprocessed cardiac medical image data, outputting a cardiac function region segmentation result, and performing post-processing on the cardiac function region segmentation result based on discrimination results of the global discriminator and the local discriminator to generate a final cardiac function region modeling result. According to the method, the segmentation precision of the heart function region, the consistency of cross-modal image segmentation and the reliability of a final segmentation result are remarkably improved.

Methods, systems, and devices for evaluating function of a heart are provided. The methods can include use of one or more imaging modalities to assess diastolic function. The methods, systems, and devices can employ various features of a cardiac volume curve to assess cardiac function. The methods, systems, and devices can be used to guide diagnosis, therapy, and / or training for sick or well patients. Methods, systems, and devices for assessing likelihood of hospital readmission for a heart failure patient are also provided.

Provided in the present application are a biomagnetic signal-based four-dimensional cardiac function imaging method and device. The method comprises: acquiring a cardiac magnetic signal of a subject to be tested and dynamic structure information of a target torso part within a full cardiac cycle, wherein the target torso part at least comprises two lungs, a torso, and a heart chamber and a pericardium structure thereof, and the dynamic structure information comprises a contour structure and a plurality of frames of dynamic images; performing spatial registration on the dynamic structure information and a sensor acquiring the cardiac magnetic signal to obtain coordinates of the sensor in a coordinate system of the dynamic structure information; calculating and reconstructing a cardiac electrical excitation activity based on the dynamic structure information, the coordinates of the sensor, and the cardiac magnetic signal to obtain a calculation and reconstruction result; and converting the calculation and reconstruction result into a four-dimensional visualization image.

An assessment of basal cardiac fitness uses noninvasively obtained physiological measures to determine the presence of a basal physiological state and cardiometric measures to determine cardiac fitness. In the presence of preload independence and cardiac vagal control, cardiometric signals are acquired that are sensitive to cardiac function and include information indicative of the opening and closing of the individual's aortic valve. The cardiometric signals are analyzed by a cardiac fitness assessment system for the determination of basal cardiac fitness. The invention assures preload independence through the assessment of observational physiological parameters or the use of physiological parameters obtained following alterations in venous return. The invention assures the presence of cardiac vagal control by assessment of measured parameters, including the presence of respiratory sinus arrhythmia. The resulting test is specific for cardiac function without dependencies on physical activities associated with heart rate elevation or respiratory capabilities.

Systems, devices and methods are provided for supporting cardiac function. A device comprises an elongate housing configured for implantation into a patient exterior to the chest cavity. The housing includes a first inlet and an outlet that define a primary blood flow path from the left atrium through at least a portion of the housing within the right atrium, and to the aorta. The housing comprises a motor disposed within the housing and an impeller coupled to the motor for pumping blood from the first inlet to the outlet of the housing through the primary blood flow path. The device bypasses the left ventricle by drawing freshly oxygenated blood from the left atrium and propelling this blood directly into the aorta. Implanting the pump exterior to the chest cavity is less invasive and allows the pump to be quickly and easily repaired, cleaned, repositioned and or replaced without removing or replacing the tubes that are anchored to sensitive tissue structures within the thoracic cavity.

The utility model relates to the technical field of medical instruments, in particular to a pacemaker electrode wire, which comprises a wire conduit, the wire conduit comprises a head part and a tail part which are connected with each other, the head part is provided with an electrode assembly, and the electrode assembly comprises a first electrode and a second electrode which are electrically connected with each other. The first electrode and the second electrode are arranged in a spaced mode in the direction from the head to the tail, and a fixing piece located between the first electrode and the second electrode is arranged on the outer side of the wire conduit. The head of the wire conduit can be sent to the right ventricular apex of the heart of a patient through vein puncture, and the fixing piece is in contact with and fixed to the surface of the endocardium, so that the first electrode is firmly fixed to the right ventricular apex, the electrode wire is kept stable in the heart of the patient, and the electrode wire is prevented from shifting or falling off; and the normal cardiac function of the patient is ensured.

The invention discloses a cardiac valve postoperative management method based on cardiac function dynamic monitoring and analysis. A multi-modal dynamic monitoring system is innovatively constructed, a comprehensive sensor array and implantable monitoring equipment are fused, and multi-dimensional data such as electrocardio, blood pressure, myocardial strain and intracardiac pressure are comprehensively collected. A personalized digital heart model is built by means of a deep learning algorithm, a real-time risk assessment and early warning system is formed by combining big data and machine learning, and heart function changes and risks are accurately predicted. According to monitoring and analysis results, a drug treatment scheme is automatically and intelligently adjusted, and a personalized rehabilitation plan covering exercise, diet and psychological guidance is customized. By means of the method, precision and individuation of cardiac valve postoperative management are achieved, data integrity and accuracy are remarkably improved, the complication occurrence rate is effectively reduced, patient compliance is enhanced, and patient rehabilitation is powerfully promoted.

The invention provides application of a DDX3X inhibitor in preparation of a medicine for treating myocardial fibrosis, and relates to the technical field of biological medicines. The invention relates to an application of a DDX3X inhibitor in preparation of a medicine for treating myocardial fibrosis. The invention proves that the myocardial cell fibrosis can be inhibited after the DDX3X is knocked down or knocked out, and the DDX3X inhibitor can interfere with the occurrence and development of mouse cardiac fibrosis and improve the cardiac function, thereby prompting that the DDX3X serving as the target of the anti-fibrosis medicine has a good medical transformation prospect, and further providing a research basis for preparing the anti-cardiac fibrosis medicine.

A blood pump may be provided for supporting heart function. A method may be provided for producing a pump housing of the blood pump. The provided blood pump comprises an implantable pump housing. The blood pump additionally comprises a fiber optic sensor comprising an optical fiber. The optical fiber is at least partially accommodated in a housing part of the pump housing.

A wearable device (100) for monitoring cardiac function during apnoeic episode. Wearable device including ballistocardiography (BCG) sensor (102A) to measure mechanical forces generated by heart and respiratory movement; electrocardiography (ECG) sensor (102B) to measure electrical activity of heart; and processor (102C) operatively connected to BCG sensor and ECG sensor to generate BCG data from measured mechanical forces and ECG data from measured electrical activity, respectively. Processor configured to: filter respiratory signals and heart signals from BCG data; detect apnoeic episode based on low respiratory signals or absence of respiratory signals for predetermined time period in filtered BCG data; determine compensatory mechanical output of heart using at least one of filtered BCG data or ECG data for apnoeic episode, and predict risk of cardiac condition based on compensatory mechanical output during apnoeic episode. Also a system (300) and method thereof.

A system and method for determining a patient's fluid-dependent hemodynamic responsiveness. The system comprises a processor configured to receive one or more of: one or more patient characteristics, one or more surgery characteristics, or one or more measured patient blood parameters. The processor is further configured to receive fluid challenge characteristics for a fluid challenge administered intravenously to the patient, and one or more measurements indicative of the patient heart function before and after the administration of the fluid challenge. The processor determines the patient blood volume (BV) within the patient's central blood compartment, before and after the administration of the fluid challenge, based on the received fluid challenge characteristics and the received one or more of: one or more patient characteristics, one or more surgery characteristics, or one or more measured patient blood parameters. The processor then calculates the relationship between the change in patient blood volume (ABV) and the change in patient heart function.

The present disclosure relates treating skeletal muscle weakness associated with heart failure by administering a compound that binds to leaky ryanodine receptors (RyRs). Compounds of the present disclosure can bind to and repair the leak in both RyR1 and RyR2 to improve skeletal muscle and cardiac function, respectively.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The invention belongs to the technical field of biological medicines, and particularly provides a small molecule compound E229-0305 for preparing a medicine for treating myocardial fibrosis. The small molecule compound E229-0305 can target PTGS2 protein, inhibit fibrosis of myocardial fibroblasts induced by TGF-beta1, reduce proliferation and migration capabilities of the myocardial fibroblasts, inhibit the fibroblasts from being converted into myofibroblasts, and inhibit expression of fibrosis-related genes and proteins. Besides, in a model of myocardial fibrosis after myocardial infarction of a mouse, the small molecule compound E229-0305 improves the cardiac function of the mouse with myocardial infarction and reduces the fibrosis area and collagen deposition of the heart. The small molecule compound E229-0305 can be used as a brand-new targeted PTGS2 small molecule inhibitor for preparing medicines for preventing and treating myocardial fibrosis.

Systems and methods and devices are provided for treating conditions such as heart failure and / or pulmonary hypertension by at least partially occluding flow through the superior vena cava for an interval spanning multiple cardiac cycles. A catheter with an occlusion device is provided along with a controller that actuates a drive mechanism to provide at least partial occlusion of the patient's superior vena cava, which reduces cardiac filling pressures, and induces a favorable shift in the patient's Frank-Starling curve towards healthy heart functionality and improved cardiac performance. The occlusion device may include a lumen obstructed by a relief valve that may permit fluid flow through the occlusion device to release an excessive build-up of pressure.

Machine-learned computational models can be trained to estimate echocardiogram parameters (as conventionally measured by echocardiography) from electrocardiograms and / or electrocardiogram-derived time-domain and / or time-frequency features. In some embodiments, a multi-level model architecture includes a level to derive the echocardiogram parameter estimate(s), with input features to that level being computed in a preceding level, and / or with one or more echocardiogram parameter estimate(s) flowing into a subsequent layer to compute downstream qualitative or quantitative indicators of heart function.

Cardiomyopathies are heart muscle disorders which represent a heterogeneous group of diseases that often lead to progressive heart failure with significant morbidity and mortality. Here, the inventors show that neutralization of acyl CoA binding protein (ACBP) / diazepam binding inhibitor (DBI) reduces the deleterious effect of the Vehicle anthracycline doxombicin on cardiac function. Since anthracycline-induced heart failure and anthracycline-induced senescence are models of accelerated cardiac aging, it is also plausible to use ACBP / DBI inhibition or neutralization as a method to prevent or treat aging of the cardiovascular system. The inventors also found that genetic and pharmacological interventions to deplete ACBP / DBI efficiently improves cardiac dysfunction associated with experimental HFpEF, a condition associated with aging, hypertension and obesity. Accordingly, the present disclosure relates to methods for the treatment of cardiac dysfunction comprising neutralization of ACBP / DBI.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to an anti-heart-failure traditional Chinese medicine composition and a pharmaceutical preparation. The traditional Chinese medicine composition comprises sun-dried ginseng, radix ophiopogonis, schisandra chinensis, American ginseng, pseudo-ginseng and poria cocos. The traditional Chinese medicine composition for resisting heart failure and the medicinal preparation provided by the invention can relieve myocardial damage and load of patients with heart failure and relieve myocardial hypertrophy and fibrosis, so that the heart function of the patients with heart failure is effectively improved.